Cytokinetics, Incorporated

CYTK · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.6%

Institutions125.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$88.04M	$18.47M	$94.59M	$70.43M	$55.83M	$26.87M	$31.50M	$4.57M	$106.41M	$28.66M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$612.26M	-$536.25M	-$324.20M	-$186.31M	-$93.94M	-$98.87M	-$88.92M	-$113.40M	$18.69M	-$37.41M
Operating income as a percentage of revenue.	-695.4%	-2902.7%	-342.8%	-264.5%	-168.3%	-368.0%	-282.3%	-2481.9%	17.6%	-130.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$785.00M	-$589.50M	-$389.00M	-$215.30M	-$127.30M	-$121.69M	-$106.29M	-$127.79M	$16.45M	-$37.50M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-6.00	$-5.00	$-4.00	$-2.80	$-1.97	$-2.00	$-1.00	$-2.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-6.00	$-5.00	$-4.00	–	–	–	–	$-2.00	$0.00	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$122.52M	$94.86M	$65.58M	$112.67M	$82.98M	$36.43M	$42.26M	$125.21M	$66.87M	$65.08M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.42B	$1.40B	$1.01B	$841.32M	$533.80M	$289.81M	$211.18M	$294.81M	$170.14M	$115.24M
All of the company's interest-bearing borrowings, short and long term combined.	$287.56M	$104.75M	$63.81M	$47.37M	$46.21M	$45.05M	$42.41M	$31.78M	$29.88M	$14.64M
Everything the company owes — debt, unpaid bills, and other obligations.	$2.08B	$1.54B	$1.12B	$597.46M	$420.42M	$300.75M	$185.24M	$184.97M	$75.78M	$46.65M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$659.63M	-$135.37M	-$107.90M	$243.86M	$113.38M	-$10.94M	$25.93M	$109.84M	$94.36M	$68.59M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$510.00M	-$395.90M	-$299.50M	-$142.50M	$8.90M	-$90.91M	-$101.22M	-$101.76M	$36.98M	$4.88M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$24.81M	$3.91M	$11.34M	$48.87M	$11.05M	$2.62M	$889000	$2.88M	$1.60M	$562000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$534.81M	-$399.81M	-$310.83M	-$191.37M	-$2.15M	-$93.53M	-$102.10M	-$104.64M	$35.39M	$4.32M

	You	Peer avg
P/E	–	44.8
Revenue Growth	-57.1%	+88.8%
ROE	–	-31.8%

Cytokinetics, Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison